ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Microbiology >Integrase Inhibitors >Elvitegravir

Elvitegravir

Elvitegravir Suppliers list
Company Name: Hangzhou Benoy Chemical Co., Ltd
Tel: +8617342059697
Email: sales@benoychem.com
Products Intro: Product Name:Elvitegravir
CAS:697761-98-1
Purity:98% Package:5KG;1KG;500g;100g
Company Name: Capot Chemical Co.,Ltd.
Tel: 571-85586718 +8613336195806
Email: sales@capotchem.com
Products Intro: Product Name:elvitegravir
CAS:697761-98-1
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:(S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-3-METHYLBUTAN-2-YL)-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
CAS:697761-98-1
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Hangzhou FandaChem Co.,Ltd.
Tel: 008657128800458; +8615858145714
Email: fandachem@gmail.com
Products Intro: Product Name:Elvitegravir
CAS:697761-98-1
Purity:As coa Package:As request Remarks:697761-98-1
Company Name: career henan chemical co
Tel: +86-0371-86658258 +8613203830695
Email: sales@coreychem.com
Products Intro: Product Name:(S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-3-METHYLBUTAN-2-YL)-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
CAS:697761-98-1
Purity:99% Package:1kg;2USD

Elvitegravir manufacturers

  • Elvitegravir
  • Elvitegravir pictures
  • $15.00 / 1KG
  • 2021-07-13
  • CAS:697761-98-1
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Elvitegravir
  • Elvitegravir pictures
  • $15.00 / 1KG
  • 2021-07-10
  • CAS:697761-98-1
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Elvitegravir
  • Elvitegravir pictures
  • $198.00 / 50mg
  • 2020-05-17
  • CAS:697761-98-1
  • Min. Order: 50mg
  • Purity: ≥98%
  • Supply Ability: 20g

Related articles

Elvitegravir Basic information
Product Name:Elvitegravir
Synonyms:Elvitegravir,EVG,GS-9137,JTK-303;(S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-3-METHYLBUTAN-2-YL)-7-METHOXY-4-OXO;6-[(3-chloro-2-fluorophenyl)Methyl]-1-[(2S)-1-hydroxy-2,3-diMethylbutan-2-yl]-7-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;GS 9137;JTK 303;6-[(3-Chloro-2-fluorophenyl)Methyl]-1,4-dihydro-1-[(1S)-1-(hydroxyMethyl)-2-Methylpropyl]-7-Methoxy-4-oxo-3-quinolinecarboxylic Acid;D06677;EVG
CAS:697761-98-1
MF:C23H23ClFNO5
MW:447.88
EINECS:1592732-453-0
Product Categories:API;Inhibitor;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;697761-98-1
Mol File:697761-98-1.mol
Elvitegravir Structure
Elvitegravir Chemical Properties
Melting point 93-96°C
Boiling point 623.6±55.0 °C(Predicted)
density 1.357±0.06 g/cm3(Predicted)
storage temp. Refrigerator
solubility DMSO (Slightly), Methanol (Slightly)
pka0.44±0.20(Predicted)
form Solid
color Off-White to Pale Yellow
InChIKeyJUZYLCPPVHEVSV-LJQANCHMSA-N
SMILESN1([C@H](CO)C(C)C)C2=C(C=C(CC3=CC=CC(Cl)=C3F)C(OC)=C2)C(=O)C(C(O)=O)=C1
CAS DataBase Reference697761-98-1
Safety Information
MSDS Information
Elvitegravir Usage And Synthesis
DescriptionIn November 2013, the European Medicines Agency (EMA) approved elvitegravir (also known as GS 9137 and JTK 303) as a single agent to be used as part of an antiviral regimen that includes a ritonavir-boosted protease inhibitor for the treatment of HIV-1 in adults without mutations indicative of elvitegravir resistance. Elvitegravir is the second of three marketed HIV integrase strand transfer inhibitors (INSTIs) including raltegravir and dolutegravir (this volume of ARMC). Elvitegravir was discovered by modification of a literature naphthyridine HIV integrase inhibitor in which the naphthyridine core served as a bioisostere for the diketo acid moiety in an original series. Serendipitously, a 4-quinolone-3-carboxylic acid precursor en route to the desired bioisosteric glyoxylic acid demonstrated modest integrase inhibition (IC50=1600 nM). Further derivatization led to elvitegravir with enhanced inhibition of integrase strand transfer (IC50=7.2 nM) and significant antiviral activity (EC50=0.9 nM). Elvitegravir was prepared in seven synthetic steps from 2,4-difluoro-5-iodobenzoic acid. The corresponding acid chloride was coupled to ethyl 3-(dimethylamino) acrylate and further substituted with S-valinol. Base promoted cyclization afforded the quinolone which was protected as silyl ether. Negishi coupling installed the 2-fluoro-3-chlorobenzyl moiety. Subsequent hydrolysis and methoxylation afforded elvitegravir.
Chemical PropertiesOff-White to Pale Yellow Solid
OriginatorTorii Pharmaceuticals (subsidiary of Japan Tobacco) (Japan)
UsesA novel inhibitor of human immunodeficiency virus type 1 integrase.
UsesElvitegravir is a quinolone antibiotic that inhibits the integrase of HIV-1 (IC50 = 7.2 nM). It blocks the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. Elvitegravir is used in combination with a pharmacoenhancer and nucleoside/nucleotide reverse transcriptase inhibitors to block HIV-1 replication in vivo.[Cayman Chemical]
UsesElvitegravir (EVG, JTK-303/GS-9137) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
DefinitionChEBI: A quinolinemonocarboxylic acid that is 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid substited at position 1 by a 1-hydroxy-3-methylbutan-2-yl group and at position 6 by a 3-chloro-2-fluorobenzyl group (the S-enantiomer). It is us d in combination therapy for the treatment of HIV-1 infection.
Brand nameVitekta? (Europe), Stribild? (as combo in the United States and Japan)
SynthesisCommercial 2,4-dimethoxy-5-bromo benzoic acid (61) was reacted with 0.5 equiv of butylethylmagnesium to generate the dimagnesium salt in THF, which was then lithiated at 20 ?? to give the aryl lithium species. The aryl lithium species was then reacted with the 2-fluoro-3-chloro benzaldehyde (62) to give alcohol 63. Treatment with triethylsilane in TFA resulted in removal of the hydroxyl functionality to provide benzoic acid 64. This acid was then reacted with carbonyldiimidazole and subsequently magnesium malonate 65 to give ketoester 66 after workup. Next, condensation with DMF¨CDMA converted ketoester 66 to the vinylogous amide 67, and this material was immediately subjected to an addition¨Celimination reaction involving (S)-valinol (68) in toluene at ambient temperature to provide intermediate 69. Warming the resulting intermediate 69 in the presence of N,Obistrimethylsilyl acetamide (BSA) and potassium chloride in DMF furnished the ring-closed quinolone 70. The ester 70 was saponified with potassium hydroxide in aqueous isopropanol and then acidified and crystallized with the use of seed crystals. Upon cooling, the crystalline product elvitegravir (IX) was collected by filtration.

Synthesis_697761-98-1

targetHIV-I integrase
Elvitegravir Preparation Products And Raw materials
Tag:Elvitegravir(697761-98-1) Related Product Information
DELAVIRDINE Orlistat Tenofovir Foscarnet sodium Succinylcholine Chloride Glutathione ISOBUTANE Tenofovir disoproxil fumarate Emtricitabine Sofosbuvir Azelnidipine 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile BMS707035 GSK1349572 Raltegravir Etravirine Atazanavir sulfate 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID